What makes the GoodLife Health telehealth membership worth paying for is the part that a lab report, a prescription app and a short office visit each leave undone. A board-certified physician reads the biomarkers that predict heart disease and diabetes, decides what to do about them and checks every 90 days whether the decision worked. GoodLife Health is built around that loop: nine biomarkers drawn at Quest four times a year, a physician who acts on every result, medication filled at the pharmacy's own price with nothing added by us and a health record that belongs to you and grows over the years.

You may already have tried to get there on your own. You asked your doctor for Apolipoprotein B (ApoB), Lipoprotein (A) and Fasting Insulin and were told insurance would not cover them. Or you paid for a panel of a hundred markers and received a long report with a dozen flags and nobody to tell you which of them mattered. Both experiences point at the same gap. Testing has become easy to buy. A physician who decides what to do with the results and then checks whether it worked, is still hard to find.

This piece sets out how we believe preventive care should work online: why we test nine biomarkers rather than a hundred, what happens after the draw and why we think that model is worth more than the alternatives. It is written by GoodLife Health, so weigh it with that in mind. We also say plainly who should choose something else.

Key Takeaways
  • The value of preventive care sits in the decision made from a result and in checking that the decision worked, more than in the number of results.
  • Nine biomarkers cover the main drivers of cardiometabolic risk: atherogenic particles, inherited risk, inflammation, blood sugar, insulin resistance and the safety markers beneath every prescription.
  • Large panels add mostly markers that rarely change treatment and every extra marker adds a chance of a false alarm.
  • A physician who acts on every panel, paid by a fee that never changes with the medication or the dose, keeps the care on the patient's side.
  • Telehealth brings this standard of care to adults in all fifty states without a half day lost to a thirty-minute visit.

Where does preventive care usually fall short?

Most people meet preventive medicine in one of three forms and each does one job well.

The annual visit screens. It is designed to find disease that is already present, on a basic panel and in a short appointment and insurance shapes what can be ordered. ApoB, Lipoprotein (A) and Fasting Insulin are often left out and a result inside the reference range is usually where the conversation ends.

The prescription app moves fast. A questionnaire, a clinician by message and a medication, often within days. Speed has value, but a prescription written before the problem has been measured leaves no baseline to judge the treatment against.

The lab-only platform measures widely. It can return dozens or hundreds of results in a polished report. What it usually cannot do is prescribe, adjust a treatment or follow you from one panel to the next, so the work of turning the report into a decision falls to you.

Each model answers part of the question. None of them closes the loop between a result, a decision and the next result and that loop is where the health benefit is earned.

Why do more biomarkers not mean better care?

A lab's reference range is set so that about 95 percent of healthy people fall inside it, which means roughly one healthy result in twenty falls outside it by chance. Across a panel of a hundred markers, a healthy person should expect several results flagged as abnormal. Some of those flags lead to repeat tests, referrals and weeks of worry about findings that were never a problem [13].

Many markers in the largest panels also have no clear treatment step attached to an abnormal result in a healthy adult or say little on a single reading without a symptom to explain them. They are interesting to read. They rarely change what a physician does next.

The question behind every test we order is simple: what are we trying to answer and will the result change what we do? Our panel is built from the markers where the answer is yes for most adults. Anything else, from testosterone and estradiol to ferritin, vitamin D and thyroid antibodies, is ordered when a symptom, a medication or a result gives a reason and is billed by the lab at its own rates.

Which nine biomarkers matter most for heart and metabolic health?

Heart disease and type 2 diabetes share a small set of causes: cholesterol-carrying particles that lodge in artery walls, an inherited particle that adds to that risk, low-grade inflammation and insulin resistance that builds for years before blood sugar rises. The nine biomarkers in our Cardiometabolic Optimization Panel measure those causes directly, alongside the safety markers every prescription depends on. Each one is paired with a decision a physician can make.

Apolipoprotein B (ApoB)

Every particle that can cause atherosclerosis, including LDL, VLDL, IDL and Lipoprotein (A), carries one ApoB molecule, so ApoB counts the harmful particles rather than measuring the cholesterol inside them. When triglycerides are high or insulin resistance is present, LDL cholesterol can look acceptable while the particle count is high [3]. The 2019 European guidelines recommend ApoB for risk assessment, particularly in people with high triglycerides, diabetes or obesity [1] and the 2018 American cholesterol guideline lists an ApoB of 130 mg/dL or more as a risk-enhancing factor [2]. The decision it drives: whether and how firmly to lower atherogenic particles and whether treatment is reaching its target.

Lipid Panel, Standard

Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and non-HDL cholesterol. LDL is an established cause of atherosclerotic disease [4] and the standard panel remains the common language of every guideline and risk calculator. Read beside ApoB, it shows whether the cholesterol and the particle count agree. The decision it drives: the starting point for treatment and the measure of whether lifestyle change or medication is working.

Lipoprotein (A)

Lipoprotein (A) is a particle whose level is largely inherited and changes little over a lifetime. A high level raises the risk of heart attack, stroke and narrowing of the aortic valve even when other lipids look good. The European Atherosclerosis Society recommends that every adult have it measured at least once [5] and the American guideline treats 50 mg/dL (125 nmol/L) or more as a risk-enhancing factor [2]. Many routine checkups never measure it. The decision it drives: how firmly to treat the risks that can be changed, because a high level raises the stakes of every other number.

Hs-CRP

High-sensitivity C-reactive protein measures low-grade inflammation, one of the processes that turns a cholesterol deposit into a heart attack. The American guideline treats a level of 2.0 mg/L or more as risk-enhancing [2]. In the JUPITER trial, adults with LDL below 130 mg/dL and an hs-CRP of 2.0 mg/L or more who took a statin had 44 percent fewer first major cardiovascular events than those on placebo [6]. It is read in bands and repeated if it was drawn during an illness. The decision it drives: whether risk is higher than cholesterol alone suggests.

Hemoglobin A1c (HbA1c)

HbA1c reflects average blood sugar over about three months. A result of 5.7 to 6.4 percent indicates prediabetes and 6.5 percent or more indicates diabetes [7]. A single result places you. The trend from panel to panel tells your physician which way you are moving. In the Diabetes Prevention Program, intensive lifestyle change reduced progression to type 2 diabetes by 58 percent and metformin by 31 percent in adults at high risk [8]. The decision it drives: when to act and whether what was started is working.

Fasting Insulin

Insulin resistance usually begins years before blood sugar rises, because the pancreas makes more insulin to hold glucose steady [9]. A Fasting Insulin drawn with fasting glucose can show that strain while HbA1c and glucose still look normal. There is no single agreed cutoff, so it is read against your glucose, triglycerides, weight and history rather than as a number on its own. The decision it drives: earlier attention to insulin resistance, before it becomes prediabetes.

Comprehensive Metabolic Panel

Kidney function, liver enzymes, fasting glucose, electrolytes and protein [10]. It is the safety floor beneath every medication decision and a raised liver enzyme can be an early sign of fatty liver disease, which often accompanies insulin resistance. The decision it drives: whether a medication is safe to start, continue or adjust.

TSH With Reflex To Free T4

TSH is the thyroid's signal and the lab adds free T4 when the TSH result calls for it. An underactive thyroid can raise LDL cholesterol and slow metabolism [11], so it belongs in any cardiometabolic picture. A result inside the range is not treated to make it look better. The decision it drives: whether a thyroid problem explains a lipid result or a symptom and whether treatment is needed.

CBC (Includes Differential And Platelets)

The complete blood count shows anemia, signs of infection and the platelet picture [12] and for anyone on testosterone it tracks the hematocrit that must be watched. The decision it drives: whether a therapy is safe to continue and whether a symptom such as fatigue has a cause in the blood.

Together, these nine describe the particles in your arteries, the inheritance behind them, the inflammation around them, the metabolic pressure building beneath them and the organs every treatment depends on. That is a complete cardiometabolic picture and every line of it can change what your physician does.

GoodLife Health. Labs, clinician, medicine, platform, $299 a month: quarterly labs, your clinician, guided GLP-1s, your data in one place. Check eligibility.GoodLife Health. Your labs, your clinician, your medicine, your data. One place. Comprehensive labs every 90 days, a board-certified clinician, branded GLP-1s when indicated, and a platform that holds it all, $299 a month. Check your eligibility.

What happens after the draw?

This is the part we believe most models undervalue and the part a membership exists to deliver.

Your first panel sets your baseline. A board-certified physician reads it against your history, your symptoms and your medications and explains in a video visit what the results mean and what, if anything, should change. When treatment is indicated, it is prescribed. When it is not, you are told why. Ninety days later, the next panel shows whether the decision worked and the plan is adjusted on your own numbers rather than on a schedule. The order is deliberate: test first, treat second.

Medication is filled at the pharmacy's own price. We add nothing to it and earn nothing from it. GLP-1 medication is branded, FDA-approved GLP-1, never compounded (Wegovy, Zepbound, Mounjaro and Ozempic). Hormone therapy, when a physician judges it indicated, is prepared by a licensed U.S. compounding pharmacy. Compounded medicines are not FDA-approved.

Every result, visit and prescription builds into your own Health Story on the GoodLife Health platform, so the picture grows over the years instead of scattering across labs, clinics and apps. Cassandra, the platform's assistant, helps you understand your own biomarkers in plain English. She explains and she does not diagnose or prescribe.

Is the membership just a convenient way to buy lab tests?

It is a fair question. The nine biomarkers in our panel can be ordered directly from a lab and if a lab result were the product, ordering it yourself would be the sensible choice.

The draw is the smallest part of what the membership does. A result changes nothing until someone with the authority to treat reads it against your history, decides what to do and checks the next panel to see whether it worked. A board-certified physician does that work with every panel, four times a year. When medication is indicated, it is filled at the pharmacy's own price with nothing added by us, so no part of the fee depends on what is prescribed. Every result builds into a record that is yours, so your fourth panel is read against the first three rather than on its own.

Convenience matters as well. A walk-in draw near you and a video visit from wherever you are replace weeks of waiting and a half day in a clinic. Convenience is what makes the care reachable. The value lies in the decisions that follow each panel.

Why does it matter how a telehealth company is paid?

How a service earns its money shapes the care it gives. A company that profits on each prescription has a reason to prescribe. One that profits on the dose has a reason to raise it. One paid for a report has little reason to follow you once the report is delivered.

The GoodLife Health membership fee is the same whatever medication is indicated and at every dose. We earn nothing on medication, so we have no reason to prescribe more, raise a dose on a timetable or move you to a cheaper product. The only way we keep a member is by being worth keeping. For a detailed look at how other models are paid, read how GLP-1 telehealth companies make money.

Why deliver this through telehealth?

The science of preventive cardiometabolic care is well established. Access to it has been the scarce part. Seeing a physician who will order and act on these markers can mean weeks of waiting and half a day spent travelling and sitting in a waiting room for a thirty-minute appointment. Many people who would benefit never get that care because the system is too slow to reach them.

Telehealth widens the reach without lowering the standard. Your panel is drawn as a walk-in test at a Quest patient service center near you, with photo ID. The results come to you and to your physician. The visit happens by video, wherever you are, in any of the fifty states. Care that once depended on living near the right clinic becomes available to anyone willing to do the work.

It has limits and we state them. A video visit cannot replace a physical examination, imaging, cancer screening, vaccines or emergency care. Keep your insurance and your primary care doctor for those. The membership works alongside them as the layer that measures and treats cardiometabolic risk continuously, so the time you spend in a clinic goes to what genuinely needs it.

What does the membership cost?

The membership is $299 a month, whatever the medication or dose. Year one is $3,588. A $598 hold is placed on your card at sign-up and covers the first two months. It is charged only once a clinician accepts you into care. If a clinician cannot accept you, the hold is released and you are never charged. Once you are accepted, the first two months are non-refundable. From the third month, it is month to month. Additional labs a physician orders beyond the quarterly panel are billed separately by the lab at its own rates. We explain the reasoning in why GoodLife Health charges two months upfront.

The fee pays for board-certified physicians in all fifty states, four Quest panels a year with every result in your hands, video visits, messages with your care team and your own health platform, which keeps your labs, visits and medication in one Health Story you can follow over the years. Medication is separate and filled at the pharmacy's own price. If you have already asked for these markers and been refused or paid for a report that nobody acted on, your first panel with us can be the one that leads to a decision.

Who is GoodLife Health not for?

If you want the largest possible panel for its own sake, a lab-only service will give you more data than we do. If you want a prescription without labs, a compounded GLP-1 or a guaranteed result, the membership is not the right fit. If you already have a physician who orders these markers, reads them with you and follows up, keep that relationship. The membership sits alongside your insurance for hospitals, specialists and emergencies. We do not bill insurance. Membership is open to adults living in the United States.

Frequently Asked Questions

What makes the GoodLife Health telehealth membership worth paying for?

A physician who reads the biomarkers that predict heart disease and diabetes, acts on them and checks every 90 days that the decision worked. GoodLife Health adds medication filled at the pharmacy's own price with nothing added by us and a health record that belongs to you.

Why does GoodLife Health test nine biomarkers instead of a hundred?

The nine cover the main drivers of cardiometabolic risk and each one can change what a physician does. Larger panels add mostly markers that rarely change treatment and each extra marker adds a chance of a false alarm. Further tests are ordered when there is a reason.

Is the GoodLife Health membership just a convenient way to buy lab tests?

No. The draw is the smallest part. A board-certified physician reads every panel, decides what to do and checks the next panel to see whether it worked, medication is filled at the pharmacy's own price with nothing added by us and every result builds into a record that is yours.

Can I order these lab tests myself?

Yes, many services sell them directly. A result on its own changes nothing. The membership adds a board-certified physician who reads every panel, decides what to do and checks the next panel to see whether it worked.

Does GoodLife Health replace my primary care doctor?

No. It works alongside your primary care doctor. Keep your doctor and your insurance for physical examinations, screenings, specialists and emergencies. The membership adds the ongoing measurement and treatment of cardiometabolic risk and your results are yours to share.

Does GoodLife Health prescribe compounded medication?

Never for GLP-1. When a GLP-1 is indicated, it is branded and FDA-approved: Wegovy, Zepbound, Mounjaro or Ozempic. Hormone therapy, when indicated, is prepared by a licensed U.S. compounding pharmacy and compounded medicines are not FDA-approved.

Related Reading

References

  1. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 2020. pubmed.ncbi.nlm.nih.gov
  2. Grundy SM, et al. 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol. Circulation, 2019. pubmed.ncbi.nlm.nih.gov
  3. Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology, 2019. doi.org
  4. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart Journal, 2017. doi.org
  5. Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 2022. pubmed.ncbi.nlm.nih.gov
  6. Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). New England Journal of Medicine, 2008. nejm.org
  7. Centers for Disease Control and Prevention. Diabetes testing. cdc.gov
  8. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 2002. nejm.org
  9. National Institute of Diabetes and Digestive and Kidney Diseases. Insulin resistance and prediabetes. niddk.nih.gov
  10. MedlinePlus. Comprehensive metabolic panel (CMP). medlineplus.gov
  11. American Thyroid Association. Hypothyroidism. thyroid.org
  12. MedlinePlus. Complete blood count (CBC). medlineplus.gov
  13. MedlinePlus. How to understand your lab results. medlineplus.gov